| Authors: |
Richner JM; Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA., Himansu S; Valera LLC, a Moderna Venture, 500 Technology Square, Cambridge, MA, 02139, USA., Dowd KA; Viral Pathogenesis Section, National Institutes of Health, Bethesda, MD 20892 USA., Butler SL; Valera LLC, a Moderna Venture, 500 Technology Square, Cambridge, MA, 02139, USA., Salazar V; Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA., Fox JM; Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA., Julander JG; Institute for Antiviral Research, Utah State University, Logan, UT, 84335 USA., Tang WW; Division of Inflammation Biology, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA., Shresta S; Division of Inflammation Biology, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA., Pierson TC; Viral Pathogenesis Section, National Institutes of Health, Bethesda, MD 20892 USA., Ciaramella G; Valera LLC, a Moderna Venture, 500 Technology Square, Cambridge, MA, 02139, USA. Electronic address: Giuseppe.Ciaramella@Valeratx.com., Diamond MS; Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO 63110, USA; The Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs, Washington University School of Medicine, St. Louis, MO 63110, USA. Electronic address: diamond@wusm.wustl.edu. |
